全球临床生物标志物检测市场,按疾病类型(癌症、代谢、传染病、心脏病学、神经病学)按应用(药物发现、营养基因组学、毒理学测试)、最终用户(制药和生物技术公司、诊断工具公司、医疗保健 IT/大数据公司)以及按地区和公司划分的行业细分展望、市场评估、竞争情景、2022-2032 年趋势和预测
- 发布日期: 2022年XNUMX月
- 报告编号: 84784
- 页数: 304
- 格式:
- keyboard_arrow_up
Clinical Biomarker Testing Маrkеt Overview:
The global clinical biomarker testing market is projected to reach a valuation of 1,30,293.84百万美元 到 2032 年 CAGR of 20.8%从 19,690.40百万美元 。
Clinical biomarker testing is a lab test that evaluates if blood protein levels are either too low, too high, or in a normal range. Biomarkers can be used to diagnose and monitor patients with diseases such as cancer and heart disease. The tests measures substances in the blood that may be elevated or decreased when an illness has been detected. Clinical biomarker testing is often used to help diagnose diseases. More than just identifying the presence of a condition, biomarker tests can also provide information on the severity and progression of a disease.
They are most often utilized in addition to other diagnostic techniques, such as imaging studies or lab work, but can be useful when these methods are not available or do not clearly indicate a definitive result. Clinical biomarkers are patient-specific markers of a disease, which may be more accurate than symptoms, and can provide more reliable information on the course of a disease. Tests for these biomarkers are very sensitive and specific compared to tests traditionally used to diagnose a condition, and can also give information on the prognosis or response to therapy. Clinical biomarkers may be more reliable as they do not depend on the subjective interpretation of symptoms by a patient.
Clinical biomarkers, which is a screening process, help to identify certain diseases or disorders. Biomarkers are often used to measure the severity of an illness or condition. For example, blood sugar levels can be tested as a biomarker for diabetes. In this scenario, people with higher levels of blood sugar would be more likely to have Type-2 diabetes than those individuals who maintained normal glucose levels. Clinical biomarkers are essential to understanding the inner workings of disease. Biomarkers are measurable substances in the body that can provide valuable information about the health of a person.
Biomarker testing is used to help physicians diagnose diseases in patients. It is most often utilized in clinical research studies where it is used to determine which treatments are more effective. Biomarkers are chemical substances found at certain levels in the body that indicate a physiological response. These tests are non-invasive, unlike other types of medical testing, and are easy for patients to provide samples for. Clinical biomarkers are a new area of medical sciences that promises to revolutionize how diseases are diagnosed and treated. Proteomics, a promising technique, that involves measuring proteins that are indicative of what is happening in the body, has already been used to successfully diagnose diseases such as HIV/AIDS, Alzheimer’s disease, and even cancer.
The use of biomarkers for clinical purposes is a relatively new scientific endeavor. This technique offers many advantages in diagnosis and treatment planning, such as providing information about the progression of a disease and the response to therapy. However, this technique also has certain disadvantages. The costs associated with these tests may be prohibitive for both doctors and patients. The process can take a long time and may delay an accurate diagnosis or treatment plan.
Global Clinical Biomarker Testing Market Revenue (USD Mn), 2021–2031:
The market for clinical biomarker testing has been designed to help healthcare providers cater to the needs of their patients. There is a need for the services of this market because clinicians typically rely on different types of data from different sources when they make a diagnosis, and often have to take samples from different areas of the body. Thus, clinicians can now use these tests to quickly determine whether they are dealing with cancerous cells or bacterial infections. Moreover, the rapid aging of global populations, combined with surging obesity rates, are elements that are expected to continue to drive the further expansion of the biomarker testing industry. Other factors contributing to the augmentation of this industry, in terms of revenue, include the increasing number of cancer medicines as well as improvements in bioinformatics.
The demand for clinical biomarkers is expected to increase in the future due to a spike in the number of individuals with diabetes. The clinical biomarker testing market is witnessing increasing interest by pharmaceutical companies in the field of biomarker-based drug development.
The demand for tailored pharmaceuticals in Europe and the United States is increasing, in turn propelling the clinical biomarker testing market forward. Furthermore, the demand for clinical biomarker testing in Europe and North America is being also driven by a growing need for toxicological technologies as well as considerable R&D efforts. As a result, Europe and North America accounted for the highest market share in 2019. On the other hand, markets in the Asia-Pacific region, pose immense growth potential on account of the growing number of clinical laboratories in countries like India and China. The high costs associated with cancer biomarker testing is a factor that is currently restraining this market’s revenue growth trajectory.
This research report on the global clinical biomarker testing market includes major company profiles such:
- 雅培公司
- 适应性生物技术
- Becton Dickinson
- Bio-Rad实验室
- 安捷伦科技公司
- Hologic公司
- 默克公司
- 赛默飞世尔科技
- 丹纳赫公司
- 艾伯维公司
- 其他
The Global Clinical Biomarker Testing Market Segmentation is Based on Disease Types, Applications, End-Users, and Region
基于疾病类型
- 癌症预防
- 代谢
- 传染病
- 心脏病
- 神经内科
- Immunological Disease
基于应用
- 药物研发
- 营养基因组学
- 毒理学测试
- 个性化医学
- 功能基因组学
基于最终用户
- 制药和生物技术公司
- 诊断工具公司
- Healthcare IT/Big Data Companies
- 临床实验室
- 研究机构
基于地区
- 北美
- 欧洲
- 亚太
- 南美
- 中东与非洲
For the Clinical Biomarker Testing Market research study, the following years have been considered to estimate the market size:
属性 报告详情 历史年代
2016-2020
基础年
2021
预计年份
2022
短期预测年份
2028
预计年份
2023
长期预测年
2032
报告范围
竞争格局、收入分析、公司份额分析、制造商分析、制造商数量、关键细分市场、关键公司分析、市场趋势、分销渠道、市场动态、COVID-19 影响分析、现有参与者获取最大市场份额的策略,以及更多的。
区域范围
北美,欧洲,亚太地区,南美,中东和非洲
国家范围
美国、加拿大和墨西哥、德国、法国、英国、俄罗斯和意大利、中国、日本、韩国、印度和东南亚、巴西、阿根廷、哥伦比亚等沙特阿拉伯、阿联酋、埃及、尼日利亚和南非
- 雅培公司
- 适应性生物技术
- Becton Dickinson
- Bio-Rad Laboratories, Inc. 公司简介
- 安捷伦科技公司公司简介
- Hologic公司
- 默克公司
- 赛默飞世尔科技
- 丹纳赫公司公司简介
- 艾伯维公司公司简介
- 其他
- 设置个人设置
我们的客户
单个用户
$5,999
$2,999
美元/每单位
保存50% |
多用户
$7,999
$3,499
美元/每单位
保存55% |
企业用户
$12,999
$4,499
美元/每单位
保存65% | |
---|---|---|---|
电子门禁 | |||
报告库访问 | |||
数据集 (Excel) | |||
打印 | |||
公司简介库访问 | |||
互动式仪表板 | |||
免费定制 | 没有 | 长达 10 小时的工作 | 长达 30 小时的工作 |
无障碍 | 1用户 | 2-5 用户 | 无限次 |
分析师支持 | 最长可达20小时 | 最长可达40小时 | 最长可达50小时 |
好处 | 下次购买最高可享受 20% 的折扣 | 下次购买最高可享受 25% 的折扣 | 下次购买最高可享受 30% 的折扣 |
立即购买(2,999 美元) | 立即购买(3,499 美元) | 立即购买(4,499 美元) |